Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1397313 | European Journal of Medicinal Chemistry | 2014 | 10 Pages |
•Dual site modulators of insulin-degrading-enzyme were discovered by screening.•X-ray structure of co-crystals and preliminary structure–activity relationships are described.•Selective inhibition of amyloid-beta degradation over insulin hydrolysis was possible.•Neuroblastoma cells treated with compounds display a dose-dependent increase in amyloid-beta levels.
Insulin degrading enzyme (IDE) is a highly conserved zinc metalloprotease that is involved in the clearance of various physiologically peptides like amyloid-beta and insulin. This enzyme has been involved in the physiopathology of diabetes and Alzheimer's disease. We describe here a series of small molecules discovered by screening. Co-crystallization of the compounds with IDE revealed a binding both at the permanent exosite and at the discontinuous, conformational catalytic site. Preliminary structure–activity relationships are described. Selective inhibition of amyloid-beta degradation over insulin hydrolysis was possible. Neuroblastoma cells treated with the optimized compound display a dose-dependent increase in amyloid-beta levels.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide